Moffitt Cancer Center Researchers Conduct Pilot Study

Article

Pensacola, FL - Researchers at the Moffitt Cancer Center in Tampa, Florida are conducting a pilot study of ActiGraph’s CentrePoint Data Hub in a sample of participants enrolled in an ongoing cancer quality-of-life study. ActiGraph is a leading provider of clinical-grade wearable activity and sleep monitoring solutions for the global scientific community.

Pensacola, FL - Researchers at the Moffitt Cancer Center in Tampa, Florida are conducting a pilot study of ActiGraph’s CentrePoint Data Hub in a sample of participants enrolled in an ongoing cancer quality-of-life study. ActiGraph is a leading provider of clinical-grade wearable activity and sleep monitoring solutions for the global scientific community. The company’s new CentrePoint Data Hub is a home-based cellular communication device that provides the Moffitt research team with a unique opportunity to remotely monitor the real-world physical activity and sleep behavior of study participants.
 
Headed by Heather Jim, PhD, from Moffitt's Health Outcomes & Behavior Program, the pilot study involves a subset of participants from an ongoing study that includes physical activity and sleep assessments using ActiGraph activity monitors. Participants in the pilot were also given a CentrePoint Data Hub, which is placed in the home and uses Bluetooth and cellular technologies to automatically upload activity monitor data to the CentrePoint software system each day. Dr. Jim and her team can login to the system to view daily information about participant wear compliance, physical activity, and sleep behavior.
 
“We’ve used ActiGraph activity monitors at Moffitt for several years, and having the ability to view participant data while the device is still in the field is a really exciting development,” said Dr. Jim. “Missing data is always a concern in any research study, but with this new technology, we can see when a volunteer isn’t wearing their activity monitor, and we can reach out with a reminder before the data collection opportunity has passed.”
 
Moffitt Cancer Center joins several other academic research organizations and clinical innovation groups that have deployed the CentrePoint Data Hub to obtain actionable, real-world data without adding unnecessary technical burden to study participants and research personnel.
 
“Because the CentrePoint Data Hub pushes data to the cloud via cellular network, our clients can avoid in-home technology issues associated with smartphone apps, subject training on those apps, and the various operating systems out there,” said Matt Biggs, ActiGraph’s Vice President of Account Services and Named Accounts. “The less burdensome and more efficient we can make our products, the better we’ll be able to help with adoption,” Biggs adds. “We’re encouraged to see Dr. Jim’s team at Moffitt, and others, really embrace this new technology as a way to improve their research capabilities and efficiency.”
 
Women without cancer who are interested in participating in Dr. Jim’s study should contact Research Coordinator Brittany Kennedy at 813-745-2168 or email GYNstudy@Moffitt.org. Assessments involve wearing an ActiGraph wrist-worn activity monitor, completing self-report questionnaires, and providing a blood sample. These data help to better understand and improve quality of life for gynecologic cancer. Volunteers are paid $25 per study assessment they complete, up to $225.
 
About ActiGraph
ActiGraph is the leading provider of clinical-grade physical activity and sleep/wake monitoring solutions for the global scientific community. ActiGraph’s innovative CentrePoint platform leverages cloud, mobile, and wireless technologies to securely deliver actionable, real world patient data in near real time. ActiGraph hardware and software solutions have been used to capture high quality objective measures in dozens of clinical trials and thousands of health research and population studies, including the U.S. National Health and Nutrition Examination Survey (NHANES), the Harvard Women’s Health Study, the NAKO Health Study, and the U.K. Millennium Cohort Study.

Recent Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.